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Abstract 28 
Objective: To quantitatively assess and compare the quality of life (QoL) of women with a 29 
self-reported diagnosis of lower limb lymphedema (LLL), to women with lower limb 30 
swelling (LLS), and to women without LLL or LLS following treatment for endometrial 31 
cancer.  32 
Methods: 1399 participants in the Australian National Endometrial Cancer Study were sent a 33 
follow-up questionnaire 3–5 years after diagnosis. Women were asked if they had 34 
experienced swelling in the lower limbs and, if so, whether they had received a diagnosis of 35 
lymphedema by a health professional. The 639 women who responded were categorised as: 36 
Women with LLL (n = 68), women with LLS (n = 177) and women without LLL or LLS (n = 37 
394). Multivariable-adjusted generalized linear models were used to compare women’s 38 
physical and mental QoL by LLL status.  39 
Results: On average, women were 65 years of age and 4 years after diagnosis. Women with 40 
LLL had clinically lower physical QoL (M=41.8, SE=1.4) than women without LLL or LLS 41 
(M=45.1, SE=0.8, p =.07), however, their mental QoL was within the normative range 42 
(M=49.6; SE= 1.1 p =1.0). Women with LLS had significantly lower physical (M= 41.0, 43 
SE=1.0, p = .003) and mental QoL (M=46.8; SE=0.8, p <.0001) than women without LLL or 44 
LLS (Mental QoL: M=50.6, SE=0.8).  45 
Conclusion: Although LLL was associated with reductions in physical QoL, LLS was related 46 
to reductions in both physical and mental QoL 3-5 years after cancer treatment. Early referral 47 
to evidence-based lymphedema programs may prevent long-term impairments to women’s 48 
QoL.  49 
Keywords: endometrial cancer; lymphedema; lower-limb swelling; quality of life  50 
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INTRODUCTION 51 
Secondary lymphedema is an accumulation of fluid in body tissues resulting from 52 
damage to the lymphatic system. The condition is relatively common after cancer treatment: 53 
around one fifth of women will develop upper limb lymphedema (ULL) following breast 54 
cancer [1], and up to one third of women report either lower limb swelling or a diagnosis of 55 
lower limb lymphedema (LLL) following gynecological cancer treatment [2-5]. People 56 
affected by lymphedema following cancer treatment can experience changes in the 57 
appearance (e.g., swelling) and function of their upper or lower limb(s); other symptoms 58 
include heaviness, aching, tingling, numbness, and pain [4, 6], which may contribute to 59 
reduced quality of life (QoL) [5, 7, 8]. While the negative impact of ULL on women’s QoL 60 
following breast cancer treatment is well known [9-12], comparatively fewer studies have 61 
examined the QoL of women with LLL following gynecological cancer treatment.  62 
Treatment (e.g., surgery, lymph node removal, adjuvant pelvic radiation therapy) and 63 
patient factors (e.g., obesity) common to gynecological cancer are also strong risk factors for 64 
secondary LLL [2, 3, 13, 14]. Women who experience the physical symptoms of LLL, 65 
occurring in the legs, feet and groin, may have reduce mobility and independence, 66 
contributing to feelings of isolation, distress and hopelessness, increasing pressure on social 67 
and intimate relationships [5, 7]. Much of the existing research on LLL following 68 
gynecological cancer treatment  has focused on short-term QoL outcomes, and results are 69 
largely based on small studies [7]. In addition, although endometrial cancer is the most 70 
common form of gynecological cancer in developed countries [15], few studies have 71 
examined the QoL of women with LLL several years following their endometrial cancer 72 
treatment [16]. 73 
Furthermore, definitions of what constitutes lymphedema and how to best measure 74 
and diagnose it vary (especially at the very early stage). Some people may have symptoms 75 
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suggestive of LLL following their cancer treatment but will not be diagnosed by a health 76 
professional [17]. Studies of breast cancer survivors suggest that arm problems/swelling, 77 
which may be undiagnosed ULL, may contribute to reductions in women’s QoL [18-20]. The 78 
severity of symptoms of lymphedema may also be an important factor influencing QoL [21, 79 
22]. However, there are no studies comparing the impact of diagnosed lower limb 80 
lymphedema (LLL) and lower limb swelling without a diagnosis of lymphedema (LLS) on 81 
the QoL of women treated for endometrial cancer. The aim of this study was, therefore, to 82 
examine the QoL of women treated for endometrial cancer 3-5 years previously, comparing 83 
those with and without self-reported secondary LLL or LLS.  84 
METHODS 85 
The cohort of women in this study participated in the Australian National 86 
Endometrial Cancer Study (ANECS), an Australia-wide, population-based, case-control study 87 
conducted between 2005 and 2007 [23]. Briefly, 2231 Australian women aged 18–79 years, 88 
who were newly diagnosed with endometrial cancer during this period, were invited to 89 
participate. Of these, 1497 (67%) agreed to take part and 1399 were confirmed as eligible and 90 
completed a telephone interview with a research nurse. Interviews were conducted around the 91 
time of diagnosis to collect information on potential predisposing factors for endometrial 92 
cancer. 93 
  Three to five years after their initial interview, women were asked to complete a 94 
follow-up mail survey to collect self-report data regarding lymphedema, physical and mental 95 
QoL, other aspects of their current lifestyle and supportive care needs [24]. Of the 1399 96 
original ANECS participants, 116 had died. Of the remaining 1283 women, 639 (49.8%) 97 
refused to participate, could not be contacted or were too unwell, leaving 644 (50.2%) 98 
women who returned a completed follow-up survey. Of these, 639 provided valid data for the 99 
questions assessing lymphedema and had not been diagnosed with this condition prior to their 100 
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diagnosis of endometrial cancer. The study was approved by the Human Research Ethics 101 
Committees at the QIMR Berghofer Medical Research Institute and all participating 102 
hospitals.  103 
Measures 104 
Lymphedema. A series of questions, with satisfactory face validity, from another 105 
Australian study of women with gynecological cancer [13] was used to categorize women 106 
into three groups. Women were asked, “Since being treated for endometrial cancer, have you 107 
experienced swelling in your legs, feet or groin?” Women who responded “No” were 108 
categorized as “without lymphedema or lower limb swelling” (Without LLL or LLS; n=394). 109 
Women who responded “Yes” to this question were asked if they had ever been told by a 110 
doctor or health professional that they had lymphedema. Those women who responded “No” 111 
were categorized as “Lower limb swelling only” (LLS; n=177), while those women who 112 
responded “Yes”, were categorized as “Diagnosed lower limb lymphedema” (LLL; n=68).  113 
Women were also asked if anyone had mentioned the possibility of developing 114 
lymphedema to them when they were diagnosed or treated for endometrial cancer. Women 115 
who responded “Yes” were asked to report who mentioned it, and when this was mentioned 116 
(before, during or after treatment). Women in the LLL and LLS groups were asked further 117 
questions about the severity of their swelling in the last month (no symptoms, mild, moderate 118 
or severe) and the level of difficulty performing daily tasks as a result of swelling (no 119 
difficulty, mild, moderate or severe).  120 
Clinical variables. Information on tumor stage at diagnosis, treatment type (surgery, 121 
chemotherapy, radiotherapy, brachytherapy, other), and number of lymph nodes examined 122 
was abstracted from the diagnostic histopathology reports and medical records of consenting 123 
women. 124 
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Demographic and personal variables. Marital status, education, employment status, 125 
area of residence (urban, rural or remote) and comorbidities (e.g. hypertension, heart disease, 126 
rheumatoid arthritis) and common medications prior to diagnosis was self-reported and 127 
collected at the initial survey. At follow-up, the woman’s current age, comorbidities and 128 
weight were also collected. Comorbidities at follow-up were combined with those at the 129 
initial survey to form one overall comorbidity score and weight was used to calculate body 130 
mass index (kg/m
2
) [coded as underweight/normal (<25), overweight (25-29.9), obese (≥30)]. 131 
The question, “Is there someone available to you whom you can count on to listen to you 132 
when you need to talk?” was used as a proxy for current level of social support (categorized 133 
as: none/little, some and all of the time). 134 
Quality of life. The Medical Outcomes Study Short Form-12 (SF-12) Health Survey 135 
was used to assess physical and mental QoL [25]. The scale is made up of eight subscales 136 
(physical functioning, bodily pain, general health, physical and emotional role limitations, 137 
vitality, social functioning, and mental health), which are combined to form two summary 138 
scores - physical and mental QoL. Scores range from 0 to 100 and higher scores indicate 139 
better QoL. To assess the clinical significance of the findings and to enable comparison with 140 
US studies, SF-12 scores were standardized (M = 50, SD = 10) using US general population 141 
norms so that a score of 40 and 60 represent one standard deviation (SD) below and above 142 
the US population mean on this scale, respectively, suggesting clinically meaningful 143 
differences in QoL [26]. The SF-12 has acceptable internal consistency [27], which was also 144 
demonstrated in this study with Cronbach’s alpha = 0.87 for the physical QoL summary 145 
score, and alpha = 0.82 for the mental QoL summary score.  146 
Statistical Analysis 147 
The characteristics (measured at diagnosis) of women who completed the follow-up 148 
survey and those who did not (including those who had died) were compared using χ2 tests 149 
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for categorical variables, in order to check for participation bias. Following this, unadjusted 150 
and multivariable-adjusted generalized linear models compared overall physical and mental 151 
QoL and subscale scores of women with LLL, women with LLS and women without LLL or 152 
LLS. Pairwise comparisons using a Bonferroni adjustment were conducted when there was a 153 
significant main effect for the lymphedema classification variable. For unadjusted models, we 154 
also calculated effect sizes (Cohen’s d) to assess the magnitude of the difference in QoL 155 
outcomes between the groups and to make comparisons with other studies. A standardized 156 
mean difference of 0.30 to 0.80 reflects a moderate, and more than 0.80, a large effect [28].  157 
All models were adjusted for current age, BMI, social support and stage of disease at 158 
diagnosis and NSAID use in the 5 years prior to diagnosis as these variables were either 159 
associated with the outcome or explanatory variable. Other potential demographic, personal 160 
and clinical confounders (outlined above) were evaluated but not retained because they did 161 
not change age-adjusted parameter estimates by more than 10%, nor alter interpretation of the 162 
results.  163 
Additional analyses combining the LLL and LLS groups assessed (i) the relationship 164 
between the severity of swelling in the last month (no/mild symptoms versus moderate/severe 165 
symptoms) and physical and mental QoL; and (ii) whether this relationship varied according 166 
to symptom group by adding a group by severity interaction to the model. All statistical 167 
analyses were performed using SAS version 9·1 (SAS Institute Inc., Cary, NC, USA). 168 
RESULTS 169 
Compared to women who did not complete the follow-up survey (n=755), 170 
respondents to the lymphedema questions (n=639) were more likely to be middle-aged (75% 171 
aged 50-69 years) and slightly better educated (52% attended technical college or had a 172 
university degree) and less likely to be obese (43%) (all p<0.05). Clinical characteristics were 173 
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similar between respondents and non-respondents. Respondents were on average 4 years 174 
post-diagnosis at time of completing the survey.  175 
Table 1 shows that overall 11% of women reported a physician diagnosis of LLL, and 176 
28% reported LLS. Women with LLL were more likely to have a diagnosis of advanced 177 
cancer; to have had more than 15 lymph nodes at initial surgery removed and to have had 178 
adjuvant radiation and/or chemotherapy compared to women without LLL or LLS; however, 179 
these groups did not differ with respect to their body size. In contrast, women with LLS had 180 
similar clinical and treatment characteristics to women without LLL or LLS, but they were 181 
more likely to be obese and to have other comorbidities than both women with LLL and 182 
women without LLL or LLS (all p<0.05).  183 
Most women with LLL or LLS reported leg swelling in the last month (78%), but 184 
swelling was more often reported as “severe” by those with LLL (15% vs. 2% respectively, p 185 
<0.001). Similarly, somewhat more women with LLL reported difficulty performing daily 186 
tasks as a result of swelling than women with LLS, but this difference was not statistically 187 
significant (21% vs. 15%, with moderate to severe difficulty, respectively, p=0.5).  188 
Adjusted mean scores for physical and mental QoL summary scales and subscales are 189 
shown in Table 2. Overall physical and mental QoL of all women treated for endometrial 190 
cancer was within the normative range. However, women with LLL had clinically lower 191 
levels of overall physical QoL, scoring more than half a SD below the mean (effect size = 192 
0.34), and they also scored significantly lower on three of the eight subscales (physical 193 
functioning, physical role limitations, and social functioning,) than women without LLL or 194 
LLS (all p<0.05). Women with LLL scored lowest on the physical functioning subscale, 195 
suggesting that they had difficulty participating in moderate activities or climbing several 196 
flights of stairs. Women with LLS had significantly lower overall physical and mental QoL 197 
and significantly lower scores for all 8 subscales than women without LLL or LLS. Effect 198 
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sizes comparing women with LLS to women without LLL or LLS were moderate (0.43-0.60) 199 
for both physical and mental subscale scores.  200 
Comparisons between the LLL and LLS groups showed no significant differences on 201 
physical QoL and mental QoL, although women with LLS tended to score lower on the 202 
mental health subscale. When these groups were combined, women who reported 203 
experiencing “moderate/severe” swelling in the last month had significantly lower overall 204 
physical QoL (M= 37.5, SE = 1.6) than women who reported only mild/no swelling (M= 205 
44.3, SE = 1.1, p<0.01), however, there was no association for mental QoL. These results did 206 
not vary when women with LLL and LLS were considered separately.  207 
DISCUSSION 208 
We examined the QoL of women who self-reported having secondary LLL or LLS 209 
following their treatment for endometrial cancer and compared this to women without LLL or 210 
LLS. Overall, 39% of women experienced either LLL (11%) or LLS (28%); these overall 211 
estimates are consistent with other studies of self-reported LLL following endometrial cancer 212 
[2, 3]. Although physical and mental QoL of the total sample of women with endometrial 213 
cancer was within the normative range [29-31], women with LLL or LLS had lower QoL 214 
scores. Specifically, women with LLL had meaningful reductions in their physical QoL 215 
relative to women without LLL or LLS, adding to existing evidence of the negative impact of 216 
lymphedema on women’s physical well being [7, 16]. Mental QoL did not differ significantly 217 
between these groups of women and this may be due to the timing of the follow-up survey 218 
and women’s access to treatment. On average, women with LLL were diagnosed 1-3 years 219 
previously so the majority had been living with the condition for several years [32]. It is 220 
possible that intervention and management of the condition facilitated  positive emotional 221 
adjustment, however, other personal, social and medical factors may also explain these 222 
findings and this warrants further research attention [33, 34].   223 
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Women with LLS had similar physical QoL to women with LLL, and had 224 
significantly lower physical QoL than women without LLL or LLS. However, in contrast to 225 
women with LLL, women with LLS had significantly lower mental QoL than women who 226 
were asymptomatic and effect sizes suggested a moderate difference between the groups. 227 
Similarly, the score for mental QoL was approaching half a SD below US population norms, 228 
suggesting subclinical levels of distress among women with LLS that should be monitored. 229 
Other studies of women with breast [18] and various cancers [35] have also found that those 230 
with undiagnosed symptoms are more likely to have reduced long-term QoL than those who 231 
have received a formal diagnosis of lymphedema. Notably, a US study of more than 1200 232 
women with breast cancer found that women with arm symptoms without diagnosed ULL, 233 
had lower mental well-being on the SF-36 QoL questionnaire, than women without arm 234 
symptoms. In contrast, women with diagnosed ULL had similar mental health to women 235 
without ULL [18]. People who have symptoms following their cancer treatment and who 236 
remain undiagnosed, may find it difficult to cope without an explanation of their symptoms 237 
and appropriate treatment advice from health professionals [18, 33].  238 
Consistent with studies of women with ULL following breast cancer [21, 22], women 239 
with recent moderate to severe swelling had lower overall physical QoL, but there was no 240 
association between the extent of swelling and mental health. Health care factors, such as the 241 
quality of provider-patient communication about lymphedema appear important for well-242 
being following cancer, [6, 36] and may better predict long-term mental health outcomes. 243 
Researchers have reported that people living with lymphedema after cancer have difficulties 244 
finding a health professional who can diagnose and treat the condition [6], and who can also 245 
provide adequate information and ongoing support [9, 13, 36]. Women who have had their 246 
lymph nodes removed and  who have pre-existing conditions, which may place them at 247 
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higher risk of swelling (e.g., obesity, diabetes, heart conditions), may benefit from 248 
information and communication about lymphedema. 249 
Women with LLL differed from women with LLS on health-related characteristics 250 
(e.g. were less likely to be obese and to have comorbidities) and on clinical characteristics 251 
(e.g., greater stage of disease and more likely to have had adjuvant treatment). Thus, reduced 252 
QoL among women with LLS may be related to having edema or other health conditions (e.g. 253 
lipedema, heart conditions) rather than having undiagnosed LLL. Obesity was also strongly 254 
associated with reduced physical QoL, and slightly attenuated the association between LLS 255 
and physical QoL. Because health professionals may find it difficult to diagnose LLL among 256 
women who are overweight or obese, QoL reductions in women who are obese and who have 257 
LLS may be explained by differences in health care.  258 
Similar to other studies using mailed surveys [37, 38], we had a relatively low 259 
response rate (50%) and, therefore, the findings may not relate well to the larger population 260 
of women with endometrial cancer. Women who were older and better educated were less 261 
likely to respond to the lymphedema questions and because these characteristics are also 262 
associated with better mental QoL among women [39, 40], our data may overestimate the 263 
levels of distress. In addition, this was a cross-sectional study and because we did not have a 264 
measure of QoL at diagnosis, we could not determine whether reduced QoL was directly the 265 
result of the LLL or LLS or of pre-existing disparities in QoL. QoL trajectories may also 266 
differ for the LLL and LLS groups and future research should longitudinally examine QoL 267 
changes. Furthermore, we may have overestimated the number of symptomatic women if 268 
women chose not to respond because they felt that they were no longer burdened by disease. 269 
On the other hand, because we only asked women about swelling following their cancer 270 
diagnosis, it is possible that some women were incorrectly classified as not having LLL. 271 
Similarly, while most women will develop symptoms of lymphedema within the first year 272 
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following their cancer treatment [8, 32], others may be diagnosed several years later and our 273 
analysis will not have captured these women. 274 
In conclusion, we show that both LLL and LLS may limit the physical QoL of long-275 
term endometrial cancer survivors, and the mental QoL of women who report experiencing 276 
swelling but who are not diagnosed with LLL. Thus, the emotional and physical well-being 277 
of women with lymphedema-like symptoms could be managed better through early referral to 278 
evidence-based lymphedema intervention programs, such as those of exercise training, 279 
bandaging or elevation [8, 41, 42]. Ongoing health care attention may be particularly 280 
important given the enormous personal and social costs associated with lymphedema [7, 8]. 281 
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Table 1: Characteristics of endometrial cancer survivors according to lymphedema status 3-5 432 
years post-cancer diagnosis (N= 639) 433 
 
Without LLL or LLS 
(n=  394) 
LLL 
(n = 68)  
LLS 
(n = 177) 
 
 N(%) N(%) N(%) P 
Current* age  M (SD) 65.2 (8.4) 65.2 (8.3) 65.4 (9.6) 0.97 
Married  273 (70.2) 51 (75.0) 108 (61.7) 0.06 
Education
 
    
High School 193 (49.0) 35 (51.5) 80 (45.2) 0.8 
Technical College 144 (36.5) 22 (32.4) 70 (39.5)  
University  57 (14.5) 11 (16.2) 27 (15.3)  
Urban area of residence 244 (63.4) 43 (64.2) 115 (65.7) 0.9 
FIGO Stage 1 at diagnosis
 
341 (86.5) 47 (70.1) 149 (84.2) 0.003 
Number of nodes examined
 
    
0 188 (49.3) 5 (7.9) 80 (46.2) <0.001 
1-14 138 (36.2) 22 (34.9) 66 (38.2)  
≥15 55 (14.4) 36 (57.1) 27 (15.6)  
Adjuvant chemotherapy  35 ( 9.1) 19 (28.8) 15 ( 8.6) <0.001 
Adjuvant radiotherapy 58 (15.1) 18 (27.3) 29 (16.4) 0.05 
Adjuvant brachytherapy  60 (15.7) 17 (25.8) 29 (16.4) 0.13 
Current BMI  (kg/m
2
)     
<24.9 135 (34.4) 24 (35.3) 31 (17.5) <0.001 
25-29.9 109 (27.7) 21 (30.9) 44 (24.9)  
>30 149 (37.9) 23 (33.8) 102 (57.6)  
Comorbidities     
Yes 148 (37.6) 28 (41.2) 86 (48.6) 0.046 
*Current at the time of follow-up survey 434 
Note. Numbers may not sum to total because some data missing435 
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Table 2: Adjusted mental and physical quality of life scores among women diagnosed with endometrial cancer 3-5 years earlier: overall and by 436 
lymphedema status  437 
SF-12 Summary and 
Subscales 
All women 
with 
endometrial 
cancer
a 
(n=  639) 
Without 
LLL or 
LLS
b 
(n=  394) 
LLL
b
  
(n= 68) 
LLS
b
  
(n = 177) 
  LLL vs. 
Without 
LLL or 
LLS 
LLS vs. 
Without 
LLL or 
LLS 
LLL 
vs. 
LLS 
 
M  (SD) M  (SE) M  (SE) M  (SE) *Effect 
size  
^Effect 
size  
P# P§ P|| 
Physical QoL summary 
 
45.1  (11.8) 45.1  (0.8) 41.8  (1.4) 41.0 (1.0) 0.34 0.54 .07 .0003 1.0 
Mental QoL summary
 
51.4 (9.8) 50.6  (0.8) 49.6  (1.1) 46.8 (0.8) 0.22 0.54 1.0 <.0001 .09 
General Health
 
45.0 (11.3) 44.8 (0.8) 43.3 (1.3) 40.2 (0.9) 0.20 0.59 .55 <.0001 .11 
Physical functioning 45.2 (11.8) 44.8 (0.8) 41.1 (1.4) 41.9 (1.0) 0.39 0.43 .03   .01 .86 
Role limitations, 
physical 
46.3 (11.3) 46.2 (0.7) 42.6 (1.3) 41.0 (0.9) 0.43 0.66 .03 <.001 .54 
Bodily Pain 48.4 (11.2) 48.6 (0.7) 45.9 (1.3) 43.9  (0.9) 0.30 0.59 .13 <.0001 .42 
Mental health 50.8 (9.2) 50.2 (0.6) 49.3 (1.1) 46.5 (0.7) 0.18 0.53 .72 <.0001 .06 
Role limitations, 
emotional 
48.5 (11.1) 48.0 (0.7) 45.5 (1.3) 43.2 (0.9) 0.38 0.61 .15 <.0001 .29 
Social functioning
 
50.2 (10.0) 49.6 (0.7) 46.6 (1.2) 46.2 (0.8) 0.45 0.53 .04 .0003 .96 
Vitality 49.1 (10.2) 48.3 (0.7) 46.8 (1.2) 44.4 (0.8) 0.26 0.60 .50 <.0001 .17 
Scores are standardised (M = 50; SD = 10) using normative data from the general USA population; higher scores indicate better functioning  438 
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a
 Unadjusted data 439 
b
 Adjusted for current age, stage, BMI, NSAID, social support 440 
* Effect size based on unadjusted data comparing women with lymphedema (LLL) to women without lymphedema or lower-limb swelling 441 
(without LLL or LLS)   442 
^Effect size based on unadjusted data comparing women with lower-limb swelling only (LLS) to women without LLL or LLS 443 
# Difference between women with LLL and women without LLL or LLS, with Bonferroni adjustment for multiple comparisons 444 
§ Difference between women with LLS and women without LLL or LLS, with Bonferroni adjustment for multiple comparisons 445 
|| Difference between women with LLL and women with LLS, with Bonferroni adjustment for multiple comparisons 446 
